List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1858190/publications.pdf Version: 2024-02-01



LILLE DE RACKER

#	Article	IF	CITATIONS
1	Hereditary thoracic aortic disease: How to save lives. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 39-45.	0.8	10
2	Arrhythmia and impaired myocardial function in heritable thoracic aortic disease: An international retrospective cohort study. European Journal of Medical Genetics, 2022, 65, 104503.	1.3	4
3	A genotype-first approach to exploring Mendelian cardiovascular traits with clear external manifestations. Genetics in Medicine, 2021, 23, 94-102.	2.4	16
4	Pregnancy Outcomes in Women After Arterial Switch Operation for Transposition of the Great Arteries: Results From ROPAC (Registry of Pregnancy and Cardiac Disease) of the European Society of Cardiology EURObservational Research Programme. Journal of the American Heart Association, 2021, 10, e018176.	3.7	14
5	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
6	Pathogenic variants in THSD4, encoding the ADAMTS-like 6 protein, predispose to inherited thoracic aortic aneurysm. Genetics in Medicine, 2021, 23, 111-122.	2.4	25
7	Transfer and transition practices in 96 European adult congenital heart disease centres. International Journal of Cardiology, 2021, 328, 89-95.	1.7	12
8	Different levels of care for follow-up of adults with congenital heart disease: a cost analysis scrutinizing the impact on medical costs, hospitalizations, and emergency department visits. European Journal of Health Economics, 2021, 22, 951-960.	2.8	5
9	QRS Duration During Follow-Up of Tetralogy of Fallot: How Valuable is it? Analysis of ECG Changes in Relation to Pulmonary Valve Implantation. Pediatric Cardiology, 2021, 42, 1488-1495.	1.3	4
10	2020 ESC Guidelines for the management of adult congenital heart disease. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 436.	0.6	12
11	Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC). International Journal of Cardiology Congenital Heart Disease, 2021, 3, 100107.	0.4	5
12	Aortic disease in Marfan syndrome is caused by overactivation of sGC-PRKG signaling by NO. Nature Communications, 2021, 12, 2628.	12.8	28
13	Cardiomyopathy in Genetic Aortic Diseases. Frontiers in Pediatrics, 2021, 9, 682390.	1.9	2
14	Association of Mitral Annular Disjunction With Cardiovascular Outcomes Among Patients With Marfan Syndrome. JAMA Cardiology, 2021, 6, 1177.	6.1	19
15	global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (ACNAP), the ESC Working Group on Adult Congenital Heart Disease (WG ACHD), the Association for European Paediatric and Congenital Cardiology (AEPC), the Pan-African Society of Cardiology (PASCAR). the Asia-Pacific Pediatric Cardiac Society (APPCS). the Inter-American Society of Cardiology	2.2	55
16	(IASC), the Cardiac Soc. European Heart Journal, 2021, 42, 4213-4223. Outflow Through Aortic Side Branches Drives False Lumen Patency in Type B Aortic Dissection. Frontiers in Cardiovascular Medicine, 2021, 8, 710603.	2.4	6
17	An Overview of Investigational and Experimental Drug Treatment Strategies for Marfan Syndrome. Journal of Experimental Pharmacology, 2021, Volume 13, 755-779.	3.2	5
18	Influenza Vaccination in Patients With Congenital Heart Disease in the Pre-COVID-19 Era: Coverage Rate, Patient Characteristics, and Outcomes. Canadian Journal of Cardiology, 2021, 37, 1472-1479.	1.7	1

JULIE DE BACKER

#	Article	IF	CITATIONS
19	Marfan syndrome. Nature Reviews Disease Primers, 2021, 7, 64.	30.5	99
20	Needs and Experiences of Adolescents with Congenital Heart Disease and Parents in the Transitional Process: A Qualitative Study. Journal of Pediatric Nursing, 2021, 61, 90-95.	1.5	12
21	Pregnancy outcome in thoracic aortic disease data from the Registry Of Pregnancy And Cardiac disease. Heart, 2021, 107, 1704-1709.	2.9	29
22	Disproportion and dysmorphism in an adult Belgian population with Turner syndrome: risk factors for chronic diseases?. Acta Clinica Belgica, 2020, 75, 258-266.	1.2	2
23	Genetic counselling and testing in adults with congenital heart disease: A consensus document of the ESC Working Group of Grown-Up Congenital Heart Disease, the ESC Working Group on Aorta and Peripheral Vascular Disease and the European Society of Human Genetics. European Journal of Preventive Cardiology, 2020, 27, 1423-1435.	1.8	38
24	Development of a transition program for adolescents with congenital heart disease. European Journal of Pediatrics, 2020, 179, 339-348.	2.7	12
25	MEK1/2 Inhibition in Murine Heart and Aorta After Oral Administration of Refametinib Supplemented Drinking Water. Frontiers in Pharmacology, 2020, 11, 1336.	3.5	4
26	Effects of fibrillin mutations on the behavior of heart muscle cells in Marfan syndrome. Scientific Reports, 2020, 10, 16756.	3.3	7
27	Spontaneous Right Ventricular Pseudoaneurysms and Increased Arrhythmogenicity in a Mouse Model of Marfan Syndrome. International Journal of Molecular Sciences, 2020, 21, 7024.	4.1	3
28	A new dimension in patent foramen ovale size estimation. Echocardiography, 2020, 37, 1049-1055.	0.9	6
29	Ambulatory Electrocardiographic Monitoring and Ectopic Beat Detection in Conscious Mice. Sensors, 2020, 20, 3867.	3.8	6
30	The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020. European Heart Journal, 2020, 41, 4153-4154.	2.2	135
31	Myocardial disease and ventricular arrhythmia in Marfan syndrome: a prospective study. Orphanet Journal of Rare Diseases, 2020, 15, 300.	2.7	14
32	The †Ten Commandments' in Adult Congenital Heart Disease Guidelines. European Heart Journal, 2020, 41, 4155-4155.	2.2	8
33	Creating the BELgian COngenital heart disease database combining administrative and clinical data (BELCODAC): Rationale, design and methodology. International Journal of Cardiology, 2020, 316, 72-78.	1.7	16
34	Genetics in congenital heart disease. Are we ready for it?. Revista Espanola De Cardiologia (English Ed) Tj ETQqO	0 0 rgBT //	Ovgrlock 101
35	Corrosion casting of the cardiovascular structure in adult zebrafish for analysis by scanning electron microscopy and Xâ€ray microtomography. Journal of Veterinary Medicine Series C: Anatomia Histologia Embryologia, 2020, 49, 635-642.	0.7	6

36Long-Term Healthcare Utilization, Medical Cost, and Societal Cost in Adult Congenital Heart Disease.0.2636Congenital Heart Disease, 2020, 15, 399-429.0.26

#	Article	IF	CITATIONS
37	Myocardial Function, Heart Failure and Arrhythmia in Marfan Syndrome: A Systematic Literature Review. Diagnostics, 2020, 10, 751.	2.6	19
38	Heritable Thoracic Aortic Diseases: Syndromal and Isolated (F)TAAD. , 2020, , 309-343.		3
39	Pregnancy Outcomes in Women With Cardiovascular Disease: Evolving Trends Over 10 Years in the ESC Registry of Pregnancy and Cardiac Disease (ROPAC). Obstetrical and Gynecological Survey, 2020, 75, 279-280.	0.4	0
40	Sleep apnea and the impact on cardiovascular risk in patients with Marfan syndrome. Molecular Genetics & Genomic Medicine, 2019, 7, e805.	1.2	11
41	Opinions of general and adult congenital heart disease cardiologists on care for adults with congenital heart disease in Belgium: a qualitative study. Cardiology in the Young, 2019, 29, 1368-1374.	0.8	4
42	Reply. Journal of the American College of Cardiology, 2019, 73, 529-530.	2.8	0
43	Body mass index in adults with congenital heart disease. Congenital Heart Disease, 2019, 14, 479-486.	0.2	10
44	<i>SMAD3</i> pathogenic variants: risk for thoracic aortic disease and associated complications from the Montalcino Aortic Consortium. Journal of Medical Genetics, 2019, 56, 252-260.	3.2	43
45	Real-world healthcare utilization in adult congenital heart disease: a systematic review of trends and ratios. Cardiology in the Young, 2019, 29, 553-563.	0.8	27
46	Vascular Ehlers-Danlos SyndromeÂManagement. Journal of the American College of Cardiology, 2019, 73, 1958-1960.	2.8	11
47	Staffing, activities, and infrastructure in 96 specialised adult congenital heart disease clinics in Europe. International Journal of Cardiology, 2019, 292, 100-105.	1.7	20
48	SMAD4 rare variants in individuals and families with thoracic aortic aneurysms and dissections. European Journal of Human Genetics, 2019, 27, 1054-1060.	2.8	24
49	Pregnancy outcomes in women with cardiovascular disease: evolving trends over 10 years in the ESC Registry Of Pregnancy And Cardiac disease (ROPAC). European Heart Journal, 2019, 40, 3848-3855.	2.2	209
50	Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome. Journal of Clinical Medicine, 2019, 8, 2079.	2.4	17
51	Genetic testing for aortopathies. Current Opinion in Cardiology, 2019, 34, 585-593.	1.8	3
52	Angiotensin-II receptor blockade in Marfan syndrome. Lancet, The, 2019, 394, 2206-2207.	13.7	4
53	European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet Journal of Rare Diseases, 2019, 14, 264.	2.7	23
54	Features of Marfan syndrome not listed in the Ghent nosology – the dark side of the disease. Expert Review of Cardiovascular Therapy, 2019, 17, 883-915.	1.5	46

#	Article	IF	CITATIONS
55	Multi-center Study on False Lumen Patency and Thrombosis in Type B Aortic Dissection Patients: Importance of (Minor) Side Branches. European Journal of Vascular and Endovascular Surgery, 2019, 58, e682-e683.	1.5	0
56	Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. Journal of Pediatrics, 2019, 204, 250-255.e1.	1.8	26
57	Marfan Syndrome. , 2019, , 241-254.		0
58	Pregnancy Outcomes in Women With Rheumatic Mitral Valve Disease. Circulation, 2018, 137, 806-816.	1.6	130
59	Propagation-based phase-contrast synchrotron imaging of aortic dissection in mice: from individual elastic lamella to 3D analysis. Scientific Reports, 2018, 8, 2223.	3.3	23
60	Arterial tortuosity syndrome: 40 new families and literature review. Genetics in Medicine, 2018, 20, 1236-1245.	2.4	66
61	Clinical history and management recommendations of the smooth muscle dysfunction syndrome due to ACTA2 arginine 179 alterations. Genetics in Medicine, 2018, 20, 1206-1215.	2.4	50
62	Heart failure and sudden cardiac death in heritable thoracic aortic disease caused by pathogenic variants in the <i><scp>SMAD</scp>3</i> gene. Molecular Genetics & Genomic Medicine, 2018, 6, 648-652.	1.2	9
63	Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. American Journal of Cardiology, 2018, 121, 1094-1101.	1.6	30
64	Influence of socioeconomic factors on pregnancy outcome in women with structural heart disease. Heart, 2018, 104, 745-752.	2.9	10
65	Hungarian Marfan family with large FBN1 deletion calls attention to copy number variation detection in the current NGS era. Journal of Thoracic Disease, 2018, 10, 2456-2460.	1.4	15
66	Cardiovascular Health in Turner Syndrome: A Scientific Statement From the American Heart Association. Circulation Genomic and Precision Medicine, 2018, 11, e000048.	3.6	143
67	Cardiovascular imaging in Turner syndrome: state-of-the-art practice across the lifespan. Heart, 2018, 104, 1823-1831.	2.9	22
68	Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Pediatric Cardiology, 2018, 39, 1453-1461.	1.3	14
69	A heart for fibrillin: spatial arrangement in adult wild-type murine myocardial tissue. Histochemistry and Cell Biology, 2018, 150, 271-280.	1.7	11
70	Clinical Validity of Genes for Heritable Thoracic Aortic Aneurysm and Dissection. Journal of the American College of Cardiology, 2018, 72, 605-615.	2.8	190
71	Hepatic Changes in the Fontan Circulation: Identification of Liver Dysfunction and an Attempt to Streamline Follow-up Screening. Pediatric Cardiology, 2018, 39, 1604-1613.	1.3	15
72	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	2.2	1,396

#	Article	IF	CITATIONS
73	Tailoring the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Guidelines for the Interpretation of Sequenced Variants in the <i>FBN1</i> Gene for Marfan Syndrome. Circulation Genomic and Precision Medicine, 2018, 11, e002039.	3.6	20
74	Looking for the Missing Links. Circulation Genomic and Precision Medicine, 2018, 11, e002185.	3.6	11
75	Arterial Hypertension in Turner Syndrome. Updates in Hypertension and Cardiovascular Protection, 2018, , 177-186.	0.1	0
76	Cardiovascular Manifestations in Inherited Connective Tissue Disorders. , 2018, , 617-646.		0
77	Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome. Nature Medicine, 2017, 23, 200-212.	30.7	134
78	Pregnancy in Women With SMAD3 Mutation. Journal of the American College of Cardiology, 2017, 69, 1356-1358.	2.8	8
79	Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). European Heart Journal, 2017, 38, 2683-2690.	2.2	73
80	The 2017 international classification of the Ehlers–Danlos syndromes. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2017, 175, 8-26.	1.6	1,163
81	Diagnosis, natural history, and management in vascular Ehlers–Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2017, 175, 40-47.	1.6	239
82	Organisation of care for pregnancy in patients with congenital heart disease. Heart, 2017, 103, 1854-1859.	2.9	20
83	Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. European Journal of Endocrinology, 2017, 177, G1-G70.	3.7	771
84	Long-Term Outcome of Patients with Perimembranous Ventricular Septal Defect: Results from the Belgian Registry on Adult Congenital Heart Disease. Cardiology, 2017, 136, 147-155.	1.4	34
85	The spectrum of spontaneous coronary artery dissection: illustrated review of the literature. Acta Cardiologica, 2017, 72, 599-609.	0.9	11
86	Efficacy of losartan as add-on therapy to prevent aortic growth and ventricular dysfunction in patients with Marfan syndrome: a randomized, double-blind clinical trial. Acta Cardiologica, 2017, 72, 616-624.	0.9	36
87	Sex, pregnancy and aortic disease in Marfan syndrome. PLoS ONE, 2017, 12, e0181166.	2.5	40
88	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 523-533.	7.1	113
89	Mitral valve prolapse syndrome and MASS phenotype: Stability of aortic dilatation but progression of mitral valve prolapse. IJC Heart and Vasculature, 2016, 10, 39-46.	1.1	12
90	Risk of Pregnancy in Moderate and SevereÂAortic Stenosis. Journal of the American College of Cardiology, 2016, 68, 1727-1737.	2.8	113

#	Article	IF	CITATIONS
91	Ventricular tachyarrhythmia during pregnancy in women with heart disease: Data from the ROPAC, a registry from the European Society of Cardiology. International Journal of Cardiology, 2016, 220, 131-136.	1.7	45
92	International Registry of Patients Carrying <i>TGFBR1</i> or <i>TGFBR2</i> Mutations. Circulation: Cardiovascular Genetics, 2016, 9, 548-558.	5.1	145
93	Pulmonary hypertension and pregnancy outcomes: data from the Registry Of Pregnancy and Cardiac Disease ( <scp>ROPAC</scp> ) of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 1119-1128.	7.1	164
94	FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene, 2016, 591, 279-291.	2.2	230
95	Clinical utility gene card for: Hereditary thoracic aortic aneurysm and dissection including next-generation sequencing-based approaches. European Journal of Human Genetics, 2016, 24, 146-150.	2.8	28
96	Heritable Thoracic Aortic Disorders. , 2016, , 263-294.		3
97	Physical Changes in Adolescence. Congenital Heart Disease in Adolescents and Adults, 2016, , 29-42.	0.2	0
98	Arterial hypertension in Turner syndrome. Journal of Hypertension, 2015, 33, 1342-1351.	0.5	55
99	Perspectives on the revised Ghent criteria for the diagnosis of Marfan syndrome. The Application of Clinical Genetics, 2015, 8, 137.	3.0	120
100	Managing aortic aneurysms and dissections during pregnancy. Expert Review of Cardiovascular Therapy, 2015, 13, 703-714.	1.5	8
101	Marfan and Sartans: time to wake up!: Figure 1. European Heart Journal, 2015, 36, 2131-2133.	2.2	10
102	MAT2A Mutations Predispose Individuals to Thoracic Aortic Aneurysms. American Journal of Human Genetics, 2015, 96, 170-177.	6.2	92
103	Gene panel sequencing in heritable thoracic aortic disorders and related entities – results of comprehensive testing in a cohort of 264 patients. Orphanet Journal of Rare Diseases, 2015, 10, 9.	2.7	62
104	Pregnancy in Women With a Mechanical Heart Valve. Circulation, 2015, 132, 132-142.	1.6	274
105	Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration. American Heart Journal, 2015, 169, 605-612.	2.7	44
106	Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections. , 2015, , 267-284.		0
107	Genetic Defects in TAPT1 Disrupt Ciliogenesis and Cause a Complex Lethal Osteochondrodysplasia. American Journal of Human Genetics, 2015, 97, 521-534.	6.2	39
108	Intrinsic cardiomyopathy in Marfan syndrome: results from in-vivo and ex-vivo studies of the Fbn1C1039G/+ model and longitudinal findings in humans. Pediatric Research, 2015, 78, 256-263.	2.3	45

#	Article	IF	CITATIONS
109	2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal, 2015, 36, 3075-3128.	2.2	3,902
110	Type B aortic dissection triggered by heart transplantation in a patient with Marfan syndrome. BMJ Case Reports, 2015, 2015, bcr2015211138.	0.5	11
111	Marfan Syndrome and Related Heritable Thoracic Aortic Aneurysms and Dissections. Current Pharmaceutical Design, 2015, 21, 4061-4075.	1.9	13
112	Absence of Cardiovascular Manifestations in a Haploinsufficient Tgfbr1 Mouse Model. PLoS ONE, 2014, 9, e89749.	2.5	9
113	The main pulmonary artery in adults: a controlled multicenter study with assessment of echocardiographic reference values, and the frequency of dilatation and aneurysm in Marfan syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 203.	2.7	34
114	Loeys–Dietz syndrome is a specific phenotype and not a concomitant of any mutation in a gene involved in TGF-1² signaling. Genetics in Medicine, 2014, 16, 641-642.	2.4	18
115	Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome. New England Journal of Medicine, 2014, 371, 2061-2071.	27.0	457
116	Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart, 2014, 100, 231-238.	2.9	191
117	Functional analysis of the anatomical right ventricular components: should assessment of right ventricular function after repair of tetralogy of Fallot be refined?. European Journal of Cardio-thoracic Surgery, 2014, 45, e6-e12.	1.4	18
118	Reference Values for Echocardiographic Assessment of the Diameter of the Aortic Root and Ascending Aorta Spanning All Age Categories. American Journal of Cardiology, 2014, 114, 914-920.	1.6	151
119	A different view on predictors of pulmonary hypertension in secundum atrial septal defect. International Journal of Cardiology, 2014, 176, 833-840.	1.7	63
120	Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome. Gene, 2014, 534, 40-43.	2.2	32
121	Treatment of pre-existing cardiomyopathy during pregnancy. Acta Cardiologica, 2014, 69, 193-196.	0.9	7
122	Twenty patients including 7 probands with autosomal dominant cutis laxa confirm clinical and molecular homogeneity. Orphanet Journal of Rare Diseases, 2013, 8, 36.	2.7	33
123	Multiple Aneurysms in a Patient With Aneurysms-Osteoarthritis Syndrome. Annals of Thoracic Surgery, 2013, 95, 332-335.	1.3	26
124	Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy. International Journal of Cardiology, 2013, 167, 2555-2560.	1.7	38
125	Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFÎ <sup>2</sup> signaling in FTAAD. International Journal of Cardiology, 2013, 165, 314-321.	1.7	134
126	Thoracic aortic-aneurysm and dissection in association with significant mitral valve disease caused by mutations in TGFB2. International Journal of Cardiology, 2013, 165, 584-587.	1.7	58

#	Article	IF	CITATIONS
127	Aneurysm-osteoarthritis syndrome with visceral and iliac artery aneurysms. Journal of Vascular Surgery, 2013, 57, 96-102.	1.1	31
128	Predictive model for late atrial arrhythmia after closure of an atrial septal defect. International Journal of Cardiology, 2013, 164, 318-322.	1.7	22
129	Echocardiographic Methods, Quality Review, and Measurement Accuracy in a Randomized Multicenter Clinical Trial of Marfan Syndrome. Journal of the American Society of Echocardiography, 2013, 26, 657-666.	2.8	49
130	Worsening in oxygen saturation and exercise capacity predict adverse outcome in patients with Eisenmenger syndrome. International Journal of Cardiology, 2013, 168, 1386-1392.	1.7	27
131	Characteristics of children and young adults with Marfan syndrome and aortic root dilation in a randomized trial comparing atenolol and losartan therapy. American Heart Journal, 2013, 165, 828-835.e3.	2.7	59
132	Characterization of Cardiovascular Involvement in Pseudoxanthoma Elasticum Families. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2646-2652.	2.4	62
133	Genes in Thoracic Aortic Aneurysms and Dissections - Do they Matter?: Translation and Integration of Research and Modern Genetic Techniques into Daily Clinical Practice. Aorta, 2013, 1, 135-145.	0.5	3
134	New insights into the molecular diagnosis and management of heritable thoracic aortic aneurysms and dissections. Polish Archives of Internal Medicine, 2013, 123, 693-700.	0.4	5
135	Genes in thoracic aortic aneurysms/dissections - do they matter?. Annals of Cardiothoracic Surgery, 2013, 2, 73-82.	1.7	25
136	First report of the genetic background of Marfan syndrome in Polish patients. Polish Archives of Internal Medicine, 2013, 123, 646-647.	0.4	2
137	Questioning the Pathogenic Role of the GLA p.Ala143Thr "Mutation―in Fabry Disease: Implications for Screening Studies and ERT. JIMD Reports, 2012, 8, 101-108.	1.5	44
138	Phenotypic spectrum of the SMAD3-related aneurysms–osteoarthritis syndrome. Journal of Medical Genetics, 2012, 49, 47-57.	3.2	221
139	The Ghent Marfan Trial — A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. International Journal of Cardiology, 2012, 157, 354-358.	1.7	59
140	Aggressive Cardiovascular Phenotype of Aneurysms-Osteoarthritis Syndrome Caused by Pathogenic SMAD3 Variants. Journal of the American College of Cardiology, 2012, 60, 397-403.	2.8	135
141	In-Frame Mutations in Exon 1 of SKI Cause Dominant Shprintzen-Goldberg Syndrome. American Journal of Human Genetics, 2012, 91, 950-957.	6.2	95
142	Comprehensive molecular analysis demonstrates type V collagen mutations in over 90% of patients with classic EDS and allows to refine diagnostic criteria. Human Mutation, 2012, 33, 1485-1493.	2.5	133
143	Right Ventricular Function in Patients With Eisenmenger Syndrome. American Journal of Cardiology, 2012, 109, 1206-1211.	1.6	27
144	The new Ghent criteria for Marfan syndrome: what do they change?. Clinical Genetics, 2012, 81, 433-442.	2.0	90

#	Article	IF	CITATIONS
145	The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. International Journal of Cardiology, 2011, 152, 192-195.	1.7	27
146	An Integrated Framework to Quantitatively Link Mouse-Specific Hemodynamics to Aneurysm Formation in Angiotensin II-infused ApoE â~'/â~' mice. Annals of Biomedical Engineering, 2011, 39, 2430-2444.	2.5	43
147	Applying massive parallel sequencing to molecular diagnosis of Marfan and Loeys-Dietz syndromes. Human Mutation, 2011, 32, 1053-1062.	2.5	71
148	Iron deficiency is associated with adverse outcome in Eisenmenger patients. European Heart Journal, 2011, 32, 2790-2799.	2.2	76
149	A Quantitative Comparison Between Baseline Hemodynamics and End-Stage Aneurysm Formation in ApoE â^'/â^' Mice. , 2011, , .		0
150	Short stature, severe aortic root dilation, skin hyperextensibility, extreme joint laxity and craniofacial dysmorphic features: a probable new syndrome. Clinical Dysmorphology, 2010, 19, 119-122.	0.3	0
151	Resolving in-vivo flow fields in the systemic circulation of the mouse through combined ultrasound imaging and computational fluid dynamics. , 2010, , .		0
152	Cardiovascular manifestations in men and women carrying a FBN1 mutation. European Heart Journal, 2010, 31, 2223-2229.	2.2	133
153	Expanding the phenotype of sudden cardiac death—An unusual presentation of a family with a Lamin A/C mutation. International Journal of Cardiology, 2010, 138, 97-99.	1.7	8
154	Dilated cardiomyopathy caused by a novel TNNT2 mutation—Added value of genetic testing in the correct identification of affected subjects. International Journal of Cardiology, 2010, 144, 307-309.	1.7	11
155	The revised Ghent nosology for the Marfan syndrome. Journal of Medical Genetics, 2010, 47, 476-485.	3.2	1,677
156	Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet, The, 2010, 376, 1476-1484.	13.7	330
157	Circulating Transforming Growth Factor-Î <sup>2</sup> in Marfan Syndrome. Circulation, 2009, 120, 526-532.	1.6	246
158	Short-term systolic and diastolic ventricular performance after surgical ventricular restoration for dilated ischemic cardiomyopathy. European Journal of Cardio-thoracic Surgery, 2009, 35, 995-1003.	1.4	14
159	Clinical and Molecular Study of 320 Children With Marfan Syndrome and Related Type I Fibrillinopathies in a Series of 1009 Probands With Pathogenic <i>FBN1</i> Mutations. Pediatrics, 2009, 123, 391-398.	2.1	146
160	Pathogenic <i>FBN1</i> mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: Further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion. American Journal of Medical Genetics, Part A, 2009, 149A, 854-860.	1.2	40
161	Comprehensive clinical and molecular assessment of 32 probands with congenital contractural arachnodactyly: Report of 14 novel mutations and review of the literature. Human Mutation, 2009, 30, 334-341.	2.5	81
162	Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24–32 mutation. European Journal of Human Genetics, 2009, 17, 491-501.	2.8	66

#	Article	IF	CITATIONS
163	Marfan and Marfan-like syndromes. Artery Research, 2009, 3, 9.	0.6	8
164	3.3 EFFECT OF CELIPROLOL ON PREVENTION OF CARDIOVASCULAR EVENTS IN VASCULAR EHLERS-DANLOS SYNDROME. Artery Research, 2009, 3, 153.	0.6	0
165	The Belgian Eisenmenger syndrome registry: Implications for treatment strategies?. Acta Cardiologica, 2009, 64, 447-453.	0.9	41
166	Patient-Specific Modelling of Aortic Arch Wall Shear Stress Patterns in Patients With Marfan Syndrome. , 2009, , .		0
167	Absence of arterial phenotype in mice with homozygous <i>slc2A10</i> missense substitutions. Genesis, 2008, 46, 385-389.	1.6	30
168	Arterial tortuosity syndrome: clinical and molecular findings in 12 newly identified families. Human Mutation, 2008, 29, 150-158.	2.5	295
169	A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients. Critical Reviews in Oncology/Hematology, 2008, 67, 133-138.	4.4	17
170	Effect of an Abdominal Aortic Aneurysm on Wave Reflection in the Aorta. IEEE Transactions on Biomedical Engineering, 2008, 55, 1602-1611.	4.2	58
171	Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer. Journal of the American Society of Echocardiography, 2008, 21, 1283-1289.	2.8	165
172	The expanding cardiovascular phenotype of Marfan syndrome. European Journal of Echocardiography, 2008, 10, 213-215.	2.3	10
173	Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands. Journal of Medical Genetics, 2008, 45, 384-390.	3.2	83
174	Successful alcohol septal ablation for late recurrence of left ventricular outflow tract obstruction after surgical myectomy in hypertrophic obstructive cardiomyopathy. Acta Cardiologica, 2008, 63, 271-275.	0.9	0
175	Early Surgical Experience With Loeys-Dietz: A New Syndrome of Aggressive Thoracic Aortic Aneurysm Disease. Annals of Thoracic Surgery, 2007, 83, S757-S763.	1.3	254
176	Experimental and numerical assessment of the impact of abdominal aortic aneurysms on arterial wave reflection. Computer Methods in Biomechanics and Biomedical Engineering, 2007, 10, 39-40.	1.6	10
177	Effect of Mutation Type and Location on Clinical Outcome in 1,013 Probands with Marfan Syndrome or Related Phenotypes and FBN1 Mutations: An International Study. American Journal of Human Genetics, 2007, 81, 454-466.	6.2	485
178	Marfan Syndrome. , 2007, , 1-6.		0
179	Three arginine to cysteine substitutions in the pro-alpha (I)-collagen chain cause Ehlers-Danlos syndrome with a propensity to arterial rupture in early adulthood. Human Mutation, 2007, 28, 387-395.	2.5	139
180	Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome. Clinical Genetics, 2007, 72, 188-198.	2.0	47

#	Article	IF	CITATIONS
181	The Impact of an Abdominal Aortic Aneurysm on Aortic Wave Reflection. , 2007, , .		0
182	Primary impairment of left ventricular function in Marfan syndrome. International Journal of Cardiology, 2006, 112, 353-358.	1.7	108
183	Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nature Genetics, 2006, 38, 452-457.	21.4	354
184	Echocardiographically estimated left ventricular end-diastolic and right ventricular systolic pressure in normotensive healthy individuals. International Journal of Cardiovascular Imaging, 2006, 22, 633-641.	1.5	21
185	A critical analysis of minor cardiovascular criteria in the diagnostic evaluation of patients with Marfan syndrome. Genetics in Medicine, 2006, 8, 401-408.	2.4	58
186	Aortic reflection coefficients and their association with global indexes of wave reflection in healthy controls and patients with Marfan's syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H2385-H2392.	3.2	48
187	Variability of aortic stiffness is not associated with the fibrillin 1 genotype in patients with Marfan's syndrome. Heart, 2006, 92, 977-978.	2.9	6
188	Aneurysm Syndromes Caused by Mutations in the TGF-Î <sup>2</sup> Receptor. New England Journal of Medicine, 2006, 355, 788-798.	27.0	1,490
189	Genetics of left ventricular outflow tract abnormalities. Acta Cardiologica, 2006, 61, 202-3.	0.9	0
190	The use of Tissue Doppler Imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. European Journal of Echocardiography, 2005, 6, 243-250.	2.3	23
191	A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nature Genetics, 2005, 37, 275-281.	21.4	1,543
192	Evaluation of left ventricular dimensions and function in Marfan's syndrome without significant valvular regurgitation. American Journal of Cardiology, 2005, 95, 795-797.	1.6	69
193	Effects of age, gender, and left ventricular mass on septal mitral annulus velocity (E′) and the ratio of transmitral early peak velocity to E′ (E/E′). American Journal of Cardiology, 2005, 95, 1020-1023.	1.6	125
194	DUP25 remains unconfirmed. American Journal of Medical Genetics Part A, 2004, 131A, 320-321.	2.4	4
195	Comprehensive molecular screening of theFBN1gene favors locus homogeneity of classical Marfan syndrome. Human Mutation, 2004, 24, 140-146.	2.5	210
196	Functional analysis of the common carotid artery. Journal of Hypertension, 2004, 22, 973-981.	0.5	44
197	Familiale aandoeningen van de thoracale aorta. Tijdschrift Voor Geneeskunde, 2004, 60, 840-849.	0.0	0
198	Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis, 2002, 160, 457-463.	0.8	38

#	Article	IF	CITATIONS
199	Diastolic dysfunction, infarct size, and exercise capacity in remote myocardial infarction: a combined approach of mitral E-wave deceleration time and color M-mode flow propagation velocity. American Journal of Cardiology, 2002, 89, 593-595.	1.6	6
200	QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life threatening ventricular arrhythmias. Heart, 1999, 81, 533-538.	2.9	16
201	Connective Tissue Disorders. , 0, , 537-546.		0
202	Late Complete Heart Block after Surgical Repair of an Atrial Septal Defect. , 0, , .		0
203	Treatment of pre-existing cardiomyopathy during pregnancy. , 0, .		1